The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 12, 2021

Filed:

Oct. 28, 2019
Applicant:

Sanofi, Paris, FR;

Inventors:

Dieter Kadereit, Frankfurt am Main, DE;

Michael Wagner, Frankfurt am Main, DE;

Thomas Olpp, Frankfurt am Main, DE;

Nino Meyer, Frankfurt am Main, DE;

Martin Bossart, Frankfurt am Main, DE;

Andreas Evers, Frankfurt am Main, DE;

Peyman Sakhaii, Frankfurt am Main, DE;

Pradeep K. Dhal, Cambridge, MA (US);

Paul Konowicz, Cambridge, MA (US);

James E. Stefano, Cambridge, MA (US);

Nils Poth, Frankfurt am Main, DE;

Assignee:

SANOFI, Paris, FR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/113 (2006.01); C07K 14/605 (2006.01); A61K 47/54 (2017.01); A61K 38/17 (2006.01); A61K 47/61 (2017.01); A61K 47/69 (2017.01); C07K 1/107 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61K 9/00 (2006.01); A61K 31/728 (2006.01); A61K 38/26 (2006.01); A61K 47/36 (2006.01);
U.S. Cl.
CPC ...
A61K 47/549 (2017.08); A61K 9/0019 (2013.01); A61K 31/728 (2013.01); A61K 38/1703 (2013.01); A61K 38/26 (2013.01); A61K 47/36 (2013.01); A61K 47/61 (2017.08); A61K 47/6903 (2017.08); A61P 3/04 (2018.01); A61P 3/10 (2018.01); C07K 1/1077 (2013.01); C07K 1/113 (2013.01); C07K 14/605 (2013.01);
Abstract

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L-L-L-L-Y—Rgroups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.


Find Patent Forward Citations

Loading…